www.ijarp.com ISSN 2456-9992 Page: 01-11

International Journal Advanced Research Publications

Review Article

Volume: 02
Issue: 04

EXPLORING POTENTIAL OF MARINE NATURAL PRODUCTS IN DRUG DISCOVERY AND DEVELOPMENT

V. Hariharasuthan*, N. Ramanathan, J. Karthi

Department of Pharmacognosy. Pallavan Pharmacy College, Kanchipuram, Tamil Nadu, India.

Article Received: 21 February 2026, Article Revised: 12 March 2026, Published on: 01 April 2026

***Corresponding Author: V. Hariharasuthan**

Department of Pharmacognosy. Pallavan Pharmacy College, Kanchipuram, Tamil Nadu, India.

DOI: https://doi-doi.org/101555/ijarp.8613

ABSTRACT:

Marine natural products (MNPs) are a valuable frontier in current medication discovery and development because of their unique chemical diversity and bioactivity. Sponge, tunicates, corals, algae, mollusks, and microorganisms are all marine creatures that produce structurally unique secondary metabolites with substantial therapeutic promise. Several MNP-derived medicines are already in clinical use, such as cytarabine and vidarabine (anticancer, antiviral), trabectedin (anticancer), eribulin (anticancer), and ziconotide (analgesic). These chemicals have broad pharmacological actions against cancer, infectious diseases, inflammation, cardiovascular problems, neurological ailments, and chronic pain, and they frequently operate through novel mechanisms. The development pipeline includes bioprospecting, extraction, bioassay-guided screening, isolation, structural elucidation, preclinical testing, optimisation, scale-up manufacturing, and clinical evaluation. Advances in genomics, metabolomics, synthetic biology, and sustainable biotechnology have overcome constraints such as low yield and environmental concerns, allowing for greater access to these compounds. Thus, marine ecosystems serve as an underexplored pool of bioactive chemicals with the potential to develop next-generation medicines, addressing unmet medical needs and providing fresh ways for combating drug resistance and complex disorders.

INTRODUCTION:

Because of their distinct chemical structures and biological activity, marine natural products (MNPs) have been a major focus of drug discovery efforts. Nearly 70% of the Earth's surface is made up of seas, which are home to a huge variety of creatures, including bacteria, fungi,

algae, and invertebrates. Finding new chemicals that could result in the development of new medicinal medicines is made possible by this biodiversity. Marine natural products (MNPs) are bioactive substances made by marine life that have important therapeutic promise for the treatment of human illnesses like cancer, infections, and inflammation. They also fulfil ecological functions like protecting against disease or predators. Despite difficulties with sustainable manufacture and sampling, these special compounds provide novel structures and modes of action, making the marine environment an attractive frontier for drug development. Numerous MNPs are already licensed or undergoing clinical trials for a range of medical purposes, and attempts to extract and use these substances are being improved by technological advancements like genomics and metabolomics.

IMPORTANCE OF MARINE NATURAL PRODUCTS IN DRUG DISCOVERY AND DEVELOPMENT:

DIVERSITY OF CHEMICALS:

Many bioactive substances that are structurally different from terrestrial natural products are produced by marine species. Finding new medications with distinctive modes of action requires this chemical uniqueness.

POTENTIAL FOR THERAPY:

Numerous MNPs have noteworthy pharmacological characteristics, such as anti-inflammatory, anti-cancer, and antibacterial effects. For example, the FDA authorised ziconotide, a treatment made from the venom of the cone snail, as the first marine-derived medication in 2004.

UNFULFILLED MEDICAL REQUIREMENTS:

TMNPs present viable remedies for illnesses for which there are currently no reliable cures. He quest for novel therapeutic agents to address a range of health issues is fuelling the growing interest in marine pharmacognosy.

UNIQUE CHEMICAL DIVERSITY:

Distinct Chemical Variability The physically unique and chemically varied substances produced by marine animals (algae, microorganisms, sponges, corals, and tunicates) are not typically found in terrestrial sources. offers fresh drug design scaffolds.

NOVAL MECHANISMS OF ACTION:

Innovative Action Mechanisms Numerous MNPs interact with biological targets that have yet to be discovered. This aids in the creation of medications with unique mechanisms of action that are effective against infections and cancer, among other resistant disorders.

NEW THERAPEUTICS SOURCE:

Many FDA-approved medications have marine origins, such as the anticancer medicine trameptin, which is produced from sea squirt. Ziconotide is an analgesic derived from the venom of cone snails. An derivative of dolastatin obtained from marine sources is used in the drug-antibody-drug combination of benuximab vedotin.

BROAD PHARMACOLOGICAL POSSIBILITIES ACTIVITY:

Vast pharmacological potential against cardiovascular disorders, pain, microbiological infections, inflammation, and cancer. Additionally, several substances exhibit antiviral properties, such as anti-HIV and anti-COVID.

LEADS FOR SYNTHETIC MODIFICATION:

Take the Lead in Synthetic Alteration Natural marine molecules serve as models for semi-synthetic derivatives that are safer, more stable, and more effective.

BIOTECHNOLOGY AND SUSTAINABILITY:

Biotechnology & Sustainability Sustainable manufacturing is made possible by modern methods (marine microbe culture, genetic engineering, synthetic biology), which lessen ecological harm.

ADDRESSING UNMET MEDICAL NEEDS:

Taking Care of Unmet Medical Needs MNPs are a crucial area for new drug discovery due to the limited number of new chemical classes and growing antimicrobial resistance.

OVERVIEW OF MARINE BIODIVERSITY :

When compared to terrestrial ecosystems, marine biodiversity is unparalleled. About 34–36 phyla, many of which lack terrestrial counterparts, are found in the ocean. In addition to being crucial for maintaining ecological equilibrium, this diversity offers a huge source of possible medicinal molecules. Important points consist of: Special organisms Numerous marine animals have special adaptations that lead to the synthesis of new metabolites. Soft corals and sponges, for instance, have been found to be abundant sources of bioactive substances.

[Symbionts of microbes] Microbial symbionts linked with marine organisms produce a large number of bioactive chemicals. Strong antibiotics and other medications are produced as a result of these microorganisms' frequent chemical warfare against rivals. Habitats that are not well explored Many marine environments, particularly deep-sea ecosystems, are still insufficiently understood despite their vastness. Technological developments are making it easier to explore these environments and revealing new categories of natural products.

The enormous range of life found in the world's oceans, ranging from microscopic organisms to the biggest beasts, is known as marine biodiversity. Over 90% of Earth's habitable space is made up of the seas, which make up 71% of the planet's surface and are inhabited to a vast variety of creatures, many of which have not yet been identified.Marine Biodiversity Overview. The range of life forms—plants, animals, and microorganisms—found in oceans and seas, as well as the ecosystems they create, is referred to as marine biodiversity. It encompasses biological diversity, the environment. Diversity, and genetic diversity.

IMPORTANCE OF MARINE BIODIVERSITY:

Significance of marine biodiversity the health of the earth depends on the diversity of life in the oceans, which also provide crucial ecosystem services.

1. Resilience of ecosystems:

Ecosystems with a high species diversity are better able to adjust to environmental disruptions and changes, such as a reduction in the population of one species.

2. Controlling the climate:

Half of the oxygen on Earth is produced by marine plants and other species, which also absorb enormous amounts of carbon dioxide. Human welfare: Food security, medicine, and human livelihoods all depend on marine biodiversity. For their basic needs, more than three billion people depend on marine and coastal biodiversity.

3. Protection of the coast:

Mangroves and coral reefs are examples of healthy coastal ecosystems that can shield shorelines from storms and erosion.

•MARINE NATURAL PRODUCTS AS DRUG SOURCE:

•Definition:

Chemicals and materials with therapeutic value that come from marine life, including microbes, algae, sponges, and corals

Important traits consist of:

1.Novelties in chemicals;

MNPs have the potential to be used in the identification of new drugs because over 71% of the molecular scaffolds they include are unique to marine creatures.

2.Bioactivity;

Significant bioactivity is more common in MNPs than in terrestrial natural products. Preclinical screening, for instance, reveals that 1% of marine materials have anti-tumor potential, while 0.1% come from terrestrial sources.

3.Ecological functions;

A large number of MNPs contribute to their bioactive qualities by acting as chemical barriers that protect marine species from infections and predators.

EXAMPLE OF DRUG FROM MARINE NATURAL PRODUCTS

•Examples of Drug Sources from Marine Natural Products (MNP):

1. Cytarabine and Vidarabine (antiviral and anticancer) → Sponge (Cryptotethya crypta)
2. Tunicate (Ecteinascidia turbinata) -> Anticancer drug Trabectedin (Yondelis®)
3. Ziconotide (Prialt®), an analgesic for extreme pain, → Cone snail (Conus magus)
4. Halichondrin B → Eribulin (anticancer) → Sponge (

Halichondria okadai)

5. Red algae → Carrageenan (pharmaceutical excipient, antiviral)

Marine Natural Products in Disease Treatment

Disease Area	**Marine Natural Product (MNP)**	**Source Organism**	**Drug/Application**
Cancer	Cytarabine (Ara-c)	Sponge (*Cryptotethya crypya*)	Anticancer (Leukemia, Lymphoma)
	Trabectedin (Yondelis®)	Tunicate (*Ecteinascidia turbinata*)	Anticancer (Sarcoma, Ovarian Cancer)
	Eribulin (Halaven®)	Sponge (*Halichondria okadai*)	Breast Cancer treatment
Viral Diseases	Vidarabine(Ara-A)	Sponge (*cryptotethya crypya*)	Ant- viral (herpes)
	Griffithsin	Red algae (*Griffithsia sp.*)	Anti-HIV, Anti- corona virus
	Carrageenan	Red algae (*Chondrus crispus*)	Anti-viral (HPV,HSV)
Pain /Neurologoical	Ziconotide(Prialt®)	Cone snail(*Conusmagus*)	Severe chronic pain
Inflammation	Manoalide	Sponge(*Luffariella variabillis*)	Anti-inflammatory(PLA2 in-

			hibitor)
	Pseudopterosins	Soft coral(*Pseudopterogorgia elisabethae*)	Wound healing, skin inflammation
Cardiovascular	Omega-3 fatty acids	Marine fish oils	Reduce triglycerides, heart protection
Antimicrobial	Salinosporamide A	Marine bacterium (*Salinispora tropica*)	Antibacterial,anticancer
	Marinopyrroles	Marine bacteria	Anti-MRSA activity

Potential Applications of Marine Natural Products (MNPs) in Drug Discovery and Development;

A. Cancer oncology

The reason for the strong fit DNA, microtubules, proteasomes, transcription, and translation factors are frequently the targets of marine compounds.

A key component of leukaemias, cytarabine (Ara-C) is a sponge-derived nucleoside derivative that inhibits DNA polymerase. The tunicate alkaloid Trabectedin (ET-743/Yondelis®) is a DNA minor-groove binder that regulates transcription and the tumour microenvironment, including macrophages.

Halichondrin B's synthetic equivalent, Eribulin (Halaven®), is a microtubule dynamics inhibitor that stops polymerisation. Salinispora tropica produces marizomib (Salinosporamide A), an irreversible proteasome inhibitor with significant central nervous system penetration. Marine-inspired warheads allow for targeted chemotherapy; dolastatin-inspired payloads (MMAE/MMAF) are cyanobacterial in origin and converge to commonly used ADC payloads (e.g., brentuximab vedotin). Principal benefits: Rich SAR for optimisation; novel MOAs → action in resistant tumours

B. Neurological conditions and pain Disorder:

Ziconotide (Prialt®), a non-opioid intrathecal analgesic for severe chronic pain, inhibits N-type voltage-gated Ca2+ channels by binding to cone snail peptide (ω-conotoxin MVIIA). Investigational for neuropathic pain and local anaesthesia, tetrodotoxin and saxitoxin are Na+ channel blockers (controlled delivery is required due to strict safety windows).

C. Infectious illnesses:

Vidarabine (Ara-A) is a sponge nucleoside that inhibits DNA polymerase; it has been used historically to treat herpes. Red algal carrageenan inhibits entry by binding to virion; it is being investigated for HPV/HSV (as well as device/excipient applications). A broad-spectrum

antiviral that binds to viral envelope glycans, Griffithsin (red algal lectin) is being researched for HIV, coronaviruses, and other (topical/systemic) possibilities.

D. Infections caused by bacteria, fungi, and parasites:

Marine bacterial scaffolds with anti-MRSA and wide antibacterial properties include abyssomicins, marinopyrroles, and macrolactins. In addition to its anticancer MOA, salinosporamide A has antibacterial properties. Antimalarial leads: a number of scaffolds with marine inspiration, some of which developed into synthetic derivatives (e.g., halofantrine lineage).

E. Immunology and haematology:

An anti-inflammatory and a PLA_2 inhibitor is manoalide (sponge). The anti-inflammatory glycosides found in pseudopseudopterosins (soft coral) aid in tissue repair, wound healing, and cosmetic applications. They also block eicosanoid pathways.An anti-inflammatory, anticoagulant, and immunomodulatory sulfated polysaccharide found in brown algae, fucoidan (nutraceuticals, biomaterials).

G. Enabling technology, biomaterials, and drug delivery:

A cationic polymer used in vaccinations, mucoadhesive nanoparticles, and mucosal administration is chitosan, which is found in crustacean shells.

Detailed Development Process of Marine Natural Products for Drug Discovery and Treatment

Bioprospecting (Collection and Exploration):

Identify marine organisms that contain potential bioactive chemicals. Habitats include cor al reefs, deep sea sediments, polar waters, and mangroves. Target Organisms: Invertebrates include sponges, tunicates, soft corals, bryozoans, and molluscs (such as cone snails). Algae can be red, brown, or green. Microorganisms include marine bacteria, cyanobacteria, and fungi. Rationale: Harsh marine settings (pressure, salinity, competition) drive organisms to develop distinct secondary metabolites. Sustainability: Avoid overharvesting; tiny tissue samples or microbial isolation may be employed. The tunicate (Ecteinascidia turbinata) was sampled to identify trabectedin, an anti-cancer

2. Extraction and Preliminary Screening

Objective: Obtain chemical compounds and test for biological activity.

Extraction:

Solvent extraction (methanol, ethanol, ethyl acetate) of marine tissues or microbial cultures.

Fractionation into crude extracts containing multiple compounds.

Screening (Bioassay-guided):

Phenotypic assays: Cell viability, microbial growth inhibition, anti-inflammatory tests.

Target-based assays: Proteasome inhibition, DNA polymerase inhibition, ion channel blocking.

Outcome: Identify "hits" – extracts showing promising activity.

Example:

Sponge extracts tested against leukemia cell lines led to discovery of Cytarabine (Ara-C).

3: Isolation and Structure Elucidation

Objective: Identify and characterize individual bioactive molecules.

Techniques:

Chromatography: HPLC, LC-MS, column chromatography.

Spectroscopy: NMR (1D, 2D), HRMS, UV–Vis, IR.

X-ray crystallography for 3D structures.

Outcome: Pure compounds with defined chemical structures ready for testing.

Example:

Isolation of Ziconotide peptide from cone snail venom and characterization of its disulfide-rich structure.

4: Preclinical Evaluation

Objective: Assess safety, efficacy, and mechanism before human trials.

In vitro studies:

Cancer cell lines for cytotoxicity.

Viral or bacterial cultures for antimicrobial/antiviral activity.

Mechanism studies:

DNA binding (Cytarabine, Trabectedin).

Ion channel blocking (Ziconotide).

Enzyme inhibition (Manoalide inhibits phospholipase A_2).

In vivo studies:

Rodent and non-rodent models to test pharmacokinetics (absorption, distribution, metabolism, excretion).

Toxicity studies to determine safe dose ranges.

5: Optimization (Hit → Lead → Candidate)

Objective: Improve efficacy, selectivity, stability, and safety.

Medicinal Chemistry Modifications:

Simplify complex structures.

Modify stereochemistry, add functional groups.

Create semi-synthetic or total-synthetic derivative

Pharmacokinetic Optimization:

Enhance solubility, bioavailability.

Reduce degradation in the body.

Outcome: Lead compounds ready for clinical trials.

Example:

Trabectedin is semi-synthesized from microbial precursor due to limited tunicate availability.

Eribulin is a simplified, synthetic version of Halichondrin B.

6: Supply & Scale-Up

Objective: Produce sufficient compound for trials and commercial use.

Challenges: Many marine organisms produce minute quantities.

Solutions:

Aquaculture / mariculture: Grow sponges or tunicates.

Microbial fermentation: Use bacteria or fungi that produce the compound.

Total or semi-synthesis: Chemical synthesis of complex molecules (Eribulin, Trabectedin).

Synthetic biology: Clone biosynthetic gene clusters into lab-friendly organisms.

7: Clinical Trials (Human Testing)

Objective: Assess safety and efficacy in humans.

Phase I: Safety, dosage, tolerability (small number of volunteers).

Phase II: Efficacy and side effects in patients.

Phase III: Large-scale testing to confirm effectiveness, monitor side effects, compare with standard treatments.

Regulatory Approval: Approval by FDA, EMA, or other authorities.

Example:

Ziconotide: Approved for intrathecal use in severe chronic pain after Phase III trials.

Trabectedin: Approved for soft tissue sarcoma and ovarian cancer.

8: Post-Market & Further Development

Monitor long-term safety.

Explore new indications (repurposing).

Develop derivatives or improved formulations.

Example:

Omega-3 fatty acids initially studied for lipid lowering, now also explored for neuroprotection and anti-inflammatory effects.

CONCLUSION:

Marine natural products (MNPs) are an extraordinary and mostly untapped source of new medication candidates with enormous therapeutic promise. Their structural uniqueness and different biological activities have already resulted in breakthrough medications for cancer, viral infections, and chronic pain, with ongoing research revealing novel prospects for treating inflammation, cardiovascular disease, and neurological problems. Modern methods such as genomics, metabolomics, synthetic biology, and sustainable aquaculture have strengthened the drug discovery process from marine creatures, from bioprospecting to clinical trials, assisting in the resolution of supply, scalability, and environmental concerns. Despite current challenges, the ocean remains a treasure resource of bioactive chemicals capable of meeting unmet medical needs and combating drug resistance. As a result, sustained research, innovation, and appropriate use of marine resources hold enormous promise for determining the future of pharmaceutical development and global healthcare.

REFERCENCE:

1. Harish Kumar Mishra, Pharmacognosy of marine natural products: Potential for drug discovery, Innov Pharm Pharmacother2023;11(3).
2. Gabriele M. König and Anthony D. Wright, (1995) Marine Natural Products Research: Current Directions and Future Potential.
3. Narsinh L Thakur[1], Archana N Thakur[2]and Werner E G Müller[3], (2005) Marine natural products in drug discovery.
4. Xiao Liang, Danmeng Luo, Hendrik Luesch (2019), Advances in exploring the therapeutic potential of marine natural products, volume147.
5. Jehad Almalitia, William H. Gerwick (2023), volume18, No.7 Methods in marine natural product drug discovery: what's new?

6. Rana Montaser[1] and Hendrik Luesch[1], (2012), Marine natural products: a new wave of drugs?
7. Abid H. Banday [1], Noor ul Azha[2], et., al (2024), volume59, Exploring the potential of marine natural products in drug development: A comprehensive review.
8. Carlos Jimé nez *, 2018, 9, 959−961, Marine Natural Products in Medicinal Chemistry.